Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03758950 · ClinicalTrials.gov registry record · Phase 2
Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2
A Phase 2 study, sponsored by Jeffrey Glassberg.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT03758950 is a Phase 2 study that has completed, run by Jeffrey Glassberg. The registered enrollment target is 80 participants.
The verdict
NCT03758950, a Phase 2 study, has completed, sponsored by Jeffrey Glassberg.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The study team proposes a triple-blind, placebo-controlled, phase II clinical trial of once-daily inhaled mometasone for 48 weeks (with 4-week washout at study completion) in individuals with Sickle Cell Disease (SCD) who report episodic cough or wheeze (ECW) but do not have asthma. Patients will be recruited from and followed in SCD clinics at participating sites. The primary endpoint will be a reduction in sVCAM level of 20% or more in comparison to placebo.
Interventions
- DRUG Placebo
- DRUG Mometasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-11-29 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03758950
The ClinicalTrials.gov registry entry for NCT03758950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jeffrey Glassberg, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03758950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03758950 about?
NCT03758950 is a clinical study titled "Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2". The study team proposes a triple-blind, placebo-controlled, phase II clinical trial of once-daily inhaled mometasone for 48 weeks (with 4-week washout at study completion) in individuals with Sickle Cell Disease (SCD) who report episodic cough or wheeze (ECW) but do not have asthma. Patients will be...
What is the current status of trial NCT03758950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2018-11-29. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT03758950?
The interventions under investigation include: Placebo (DRUG), Mometasone (DRUG).
Who is sponsoring clinical trial NCT03758950?
This trial is sponsored by Jeffrey Glassberg, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.